Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraine, Without Aura Clear all
Completed Not applicable Interventional

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency, Intensity, and Functionality: A Single-Arm Study

NCT06695156
View directory record Official record
Conditions
Migraine, Migraine With or Without Aura
Interventions
Meditation
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02867709
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
109
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 23, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Study of EVO756 in Adults With Migraine

NCT07616128
View directory record Official record
Conditions
Migraine
Interventions
EVO756, Dose 1, EVO756, Dose 2, Placebo
Drug
Lead sponsor
Evommune, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Stamford, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

NCT03061734
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 23, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

A Comprehensive Digital Care Program for Migraine Management

NCT07642414
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Neuromodulation Wearable Device, Migraine Digital Care Program
Device · Other
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Integrative Migraine Pain Alleviation Through Chiropractic Therapy

NCT03177616
View directory record Official record
Conditions
Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Migraine, Classic
Interventions
Chiropractic Treatment
Other
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Trial in Adult Subjects With Acute Migraines

NCT03461757
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
69
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

NCT04940390
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebo
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
127
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

NCT00382993
View directory record Official record
Conditions
Migraine Disorders
Interventions
Placebo, Combination Product (sumatriptan succinate/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jul 23, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Migraine Prevention

NCT01184508
View directory record Official record
Conditions
Migraine Headache
Interventions
Placebo, LY2300559
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Long Beach, California • Fairfield, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine in Migraine (in Clinic)

NCT00610428
View directory record Official record
Conditions
Migraine Headache, With or Without Aura
Interventions
Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Mount Vernon, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

NCT03194555
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Low-Dose Naltrexone and Acetaminophen Combination, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Adult Subjects With Acute Migraines

NCT03237845
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
50
States / cities
Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Terminated Not applicable Interventional Results available

Transnasal Cooling for Migraine

NCT04936061
View directory record Official record
Conditions
Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
Interventions
CoolStat active device, CoolStat sham device
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • East Lansing, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02828020
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Ubrogepant, Placebo-matching Ubrogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
90
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety Study of DFN-15

NCT03006276
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

NCT03338920
View directory record Official record
Conditions
Acute Migraine With or Without Aura
Interventions
sumatriptan nasal powder, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT05337254
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Jul 23, 2026, 10:22 AM EDT
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
116
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine

NCT01653522
View directory record Official record
Conditions
Migraine Disorders, Headache, Migraine, Migraine, Migraine Headache, Migraine With Aura, Migraine Without Aura, Headache Disorders, Primary
Interventions
Triptan, Doxycycline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jul 23, 2026, 10:22 AM EDT
Terminated Not applicable Interventional

Understanding the Pathophysiology of Migraine Pain

NCT03026101
View directory record Official record
Conditions
Migraine Disorders, Migraine, Classic, Migraine Without Aura
Interventions
Nitroglycerin
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 23, 2026, 10:22 AM EDT
Not yet recruiting Not applicable Interventional

Using Virtual Reality to Teach Mindfulness to People With Migraine

NCT07599228
View directory record Official record
Conditions
Migraine Disorders, Migraine With Aura, Migraine Without Aura, Episodic Migraine
Interventions
ACT therapy delivered by REACT NeuroVR headset
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Mi-Helper Transnasal Cooling for Acute Treatment of Migraine

NCT06051604
View directory record Official record
Conditions
Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Mi-Helper
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 23, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability, and Safety of DFN-15

NCT03009019
View directory record Official record
Conditions
Migraine Headache
Interventions
DFN-15 Active, DFN-15 Placebo
Drug · Other
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 75 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 23, 2026, 10:22 AM EDT